WRAIR’s Pilot Bioproduction Facility presents at the World Vaccine Congress 2025

Photo By Hannah Covington | Dr. Jennifer Grossman, Business Development Manager for the Pilot Bioproduction Facility, Walter Reed Army Institute of Research, speaks to a conference attendee about the Pilot Bioproduction Facility’s poster at the 2025 World Vaccine Conference in Washington, D.C., April 24, 2025. The World Vaccine Congress is the largest vaccine conference series in the world, bringing together industry experts across the entire vaccine landscape through panels, exhibitions, presentations, and networking. (U.S. Army photo by Hannah “Nez” Covington/RELEASED)  

WASHINGTON, DISTRICT OF COLUMBIA, UNITED STATES

05.27.2025

Story by Zeke Gonzalez 

Walter Reed Army Institute of Research

Dr. Jennifer Grossman, business development manager of the Pilot Bioproduction Facility at the Walter Reed Army Institute of Research, presented on the capabilities of the PBF at the annual World Vaccine Congress conference held in Washington D.C., April 2025.

The PBF is a cGMP-compliant facility that specializes in the production of early-stage clinical trial material, particularly vaccines and biologics. It plays a key role in supporting U.S. military and public health medical countermeasure efforts.

Dr. Grossman and other team members from WRAIR’s PBF joined more than 1,000 researchers and stakeholders at WVC 2025, one of the largest international events focused on vaccine development and manufacturing. The conference attracts top scientists, companies, and government officials from around the world. Attendees from WRAIR participated in workshops, panels, and poster sessions covering topics ranging from innovations in vaccine technology to the manufacturing of mRNA vaccines, monoclonal antibodies, and other biologics.

“WRAIR is an authority in the world of vaccines – we’ve been involved in vaccine development for many years,” Dr. Grossman said. “People don’t realize that on top of our historical role in the research, WRAIR has the PBF. It is a GMP-grade facility for phase I clinical material, with the ability to manufacture biologics for industry, academia, the Department of Defense, other government agencies, and more.”

For over a century, WRAIR has contributed to major vaccine milestones and continues to serve as a key player in military medical research. The PBF complements this legacy by enabling WRAIR to translate lab discoveries into deployable medical solutions for the Department of Defense and global partners.

“The PBF has many years of experience making vaccines for phase 1 clinical trials” said Dr. Grossman. “On top of our experience, we are developing new capabilities. The PBF is developing a platform process for manufacturing mRNA vaccines and monoclonal antibodies in addition to more traditional biologics.”

Participation in WVC 2025 helped raise awareness of WRAIR’s end-to-end capabilities in medical product development, from scientific discovery to early-stage manufacturing. With growing interest in flexible, mission-driven production platforms, the PBF is positioned to play a pivotal role in supporting emerging public health needs and strengthening global biodefense partnerships.

For more information on the Pilot Bioproduction Facility, or to contact the PBF, visit our website: https://wrair.health.mil/Collaborate/Pilot-Bioproduction-Facility/

• Date Taken: 05.27.2025
• Date Posted: 05.27.2025 16:28
• Story ID: 498977
• Location: WASHINGTON, DISTRICT OF COLUMBIA, US